Pfizer calls proposed IP waiver for Covid vaccines a 'distraction' from finding real solutions on access
While it seems obvious that Pfizer would oppose any move at the World Trade Organization to waive the company’s intellectual property rights, the mRNA powerhouse recently spelled out its immediate concerns with such a waiver in writing for the first time, calling it “a distraction from the real solutions to improve vaccine access.”
In response to a parliamentary inquiry in Australia on vaccine-related fraud and security risks, Pfizer noted that the waiver proposal at the WTO “incorrectly portrays IP as a barrier to rapid innovation, R&D collaboration and access to COVID-19 vaccines and other products. On the contrary, IP rules are enabling an unprecedented amount of innovation and facilitating collaboration between biopharma innovators and partners. Eliminating IP protections would not speed up vaccine production.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.